ArticleCancers2021

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.

Fiorella Iglesias Cardenas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.